Treatment Outcomes of Scleroderma with Janus Kinase Inhibitors: A Systematic Review

Scleroderma is a connective tissue disorder characterized by hardening and thickening of the skin. Initial treatment involves topical and systemic corticosteroid therapies, with immunosuppressive therapy in severe and refractory cases, although none are curative and outcomes are often poor. This review evaluates the efficacy and safety of novel Janus Kinase inhibitors (JAKi) therapy use in patients with cutaneous scleroderma.硬皮病（Scleroderma）是一类以皮肤硬化、增厚为特征的结缔组织疾病。初始治疗方案包括外用与系统性糖皮质激素疗法，对于重症及难治性病例则需联合免疫抑制治疗，但现有疗法均无法治愈该病，且患者预后往往不佳。本综述评估了新型Janus激酶抑制剂（Janus Kinase inhibitors, JAKi）疗法在皮肤型硬皮病（cutaneous scleroderma）患者中的疗效与安全性。